RE:RE:RE:RE:RE:RE:RE:History RepeatsCredentials.. scientist? No. Work in biotech? No. In business generally.. a little bit.
Johnny. I take Matt at his word when he says the Head and Neck phase 3 failed because...
I am on stockhouse record just before the key opinion leader conference call stating my concern about whether or not ONC wrote treatment protocols for flu like symptoms into the Breast Cancer Trial design. This seemed to be the biggest talking point of the Key Opinion Leaders. In anticipation of the call I reflected on comments Matt made a month earlier about stronger immune response in the young and healthy. And I thought oh no you've done it again.
The Head and Neck was a double blinded study. They had information to imply certain groups responded differently. In the interest of science they broke up the patient population into sub groups. As a result of smaller populations they lost statistical significance. My understanding is the control group responded much better than they anticipated and this ultimately screwed them up.
I cannt comment on Matt as a scientist. But I will say. I think he never had the confidence and committment to carrying Pela across the goal line. Always seeking the perfect solution. I would also say he overestimated how far their resources could take them. I think Matt is also naive. Be careful of your bed partners. Pfizer is pure evil. And Adalai is a Chinese National company.
As a business the share price, dilution and complete absence of a commercial product after twenty five years speaks for itself and the competence of Matt.
In closing, we all believe in Pela and the opportunity. We all believe there's a big disconnect between share price and the opportunity. I do believe we are close. I thought 2023 was our year. And it should have been if not for a screw up in trial design. I now think 2024 will be the year of inflection. Good luck to all.